PHA Pharmagest Interactive SA

Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR

Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR

Villers-lès-Nancy, 30 April 2025 - 8:00 AM (CET)

PRESS RELEASE

EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR TO ACQUIRE TWO SOFTWARE PUBLISHING BUSINESSES OPERATING IN THE PUBLIC HEALTH SECTOR

  • Project for a targeted acquisition in the public health sector:
    • Acquisition of Novaprove, publisher of the ResUrgences software,
    • Acquisition of the DIS business assets,
  • Strategic reinforcement of Equasens Group's Axigate Link division in this market segment

***

(Euronext Paris™ - Compartment B - FR 0012882389 -$EQS), today announced that through its subsidiary Axigate, publisher of the HOSPILINK electronic medical record (EMR) solution for hospitals, the Axigate Link Division has entered into exclusive negotiations with a French software solutions editor regarding the possibility of acquiring two businesses specialising in software solutions for the public healthcare sector.



Nature and scope of the proposed acquisition

This proposed acquisition covers two complementary businesses:



Firstly, ResUrgences (Novaprove), a web-based software platform specialising in the management of hospital emergency medical services featuring a new and innovative technological solution that optimises patient intake, pathway management and emergency care delivery processes.



Secondly, the comprehensive DIS (including FACDIS) suite of digital solutions for public healthcare establishments, covering accounting, billing, human resources and financial management that work seamlessly with the electronic patient record.



If this transaction is completed, these two activities would be integrated into the Axigate Link Division, a European expert in software and applications for health and medico-social establishments.

A strong strategic focus

This project is fully in line with Equasens' development strategy by seeking to reinforce its positioning and market share in the fast-growing public health software sector.

Through this acquisition, the Group also seeks to expand its portfolio of solutions by offering a more comprehensive, high value-added offering. The resulting technical and commercial synergies with the Axigate Link Division's existing solutions will be a major growth driver by optimising resources and accelerating innovation. 

Finally, this potential acquisition would contribute to consolidating the Group's position as a driving force in the digital transformation of the healthcare system, by providing increasingly customised solutions adapted to the specific needs of healthcare establishments and their practitioners.

Provisional timetable

Completion of this transaction remains subject to the information and consultation procedures with the relevant employee representation bodies, signature of the final agreements and fulfilment of the other conditions normally applicable in such matters. Equasens will keep the market informed of significant progress on this project, in accordance with its regulatory disclosure obligations.

The closing of this transaction is expected to be completed before the end of Q3 2025.

Next publication

  • 12 May 2025: Q1 2025 revenue - After the close of trading



About - Follow us also on

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.300 people across Europe.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Listed on Euronext Paris, Equasens Group applies a two-pronged development strategy combining organic growth with targeted acquisitions at a European level.

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel: +33 (0)3 83 15 90 67 -

Financial communications agency:

FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 -

Attachment



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - CA S1 : Retour de la dynamique confirmé / Achat - Obj...

CA S1 +7,4% à 116 M€ en ligne (115,4 M€ attendus) T1 : 57 M€, +6,9% (+5,9% pc) T2 : 58,9 M€, +7,8% (+6,9% pc) Apport de Calimed 1,1 M€ Intégration ResUrgenves & DIS à compter du 1er juillet.

 PRESS RELEASE

Equasens: H1 revenue at 30 June 2025: €116.0m

Equasens: H1 revenue at 30 June 2025: €116.0m Villers-lès-Nancy (France), 31 July 2025 - 6:00 PM (CET) PRESS RELEASE H1 revenue at 30 June 2025: €116.0m+7.4% on a reported basis and +6.4% like-for-like H1 2025 Group revenue (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Total108.0116.08.07.4%1.16.96.4%H1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growthPharmagest82,1...

 PRESS RELEASE

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€ Villers-lès-Nancy, le 31 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 30 juin 2025 à 116,0 M€+7,4% en croissance publiée et + 6,4% en croissance organique CA S1 2025 Groupe (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissance organique)T153,357,03,76,9%0,53,25,9%T254,758,94,37,8%0,53,86,9%Total108,0116,08,07,4%1,16,96,4%CA S1 2025 / Division (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissan...

 PRESS RELEASE

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of Fran...

 PRESS RELEASE

EQUASENS : Nomination à la direction de la Division Pharmagest

EQUASENS : Nomination à la direction de la Division Pharmagest Villers-lès-Nancy, le 03 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Equasens annonce le départ de Damien VALICON, Directeur Général Délégué et Directeur de la Division PHARMAGEST Il sera remplacé par François-Pierre MARQUIER en tant que Directeur de la Division Pharmagest *** (Euronext Paris™ - Compartiment B - FR 0012882389 –$EQS), annonce le départ de Damien VALICON, qui occupait depuis 18 mois les fonctions de Directeur Général Délégué du Groupe et de Directeur de la Division PHARMAGEST, ainsi que la nomination de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch